Forum Agenda
-
Keynote Forum: The Global Journey of China’s Innovation Drugs
-
-
Future-Driven Intelligent R&D–AI for Life Sciences and Drug Discovery
-
The Era of Superintelligent Agents for Chinese Innovative Drugs
-
Panel Discussion: AI-Empowered Four-in-One Translation Platform
-
AI-Driven Innovation Practices in Pharmaceutical Enterprises
-
AI·Intelligent Transformation: From Data Foundation to Scenario Value
-
-
Medicine-Engineering Integration and Innovative Medical Devices
-
Cross-Border Cooperation and China’s New Drug Global Expansion
-
Global Development of Pharma Enterprises and Emerging Market Cooperation
-
China-Japan Cooperation Session: Leveraging Japan’s Market to Boost Overseas Expansion Strategies
-
Legal Safeguard and Value Empowerment for Globalization of Chinese Pharma Enterprises
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
Global BD Cooperation Session for Innovative Drugs – Track 1, 2 & 3
-
Collaboration Between North American and Chinese Innovative Drug Industries
-
Biosimilars Commercialization & Global Launch Session(China Focus)
-
Protheragen Session: Global Biomedical Cross-Border Transactions
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
U.S. Biotech Tensions and the Future Road for Chinese Pharmaceutical Companies Going Global Session
-
July 24,09:00-11:40
Novel Anti-Tumor and Autoimmune Therapeutics Session
Stay tuned
09:00-09:20 Personalized Cancer Immunotherapy: Current Status and Future
Bin Li: Researcher, Shanghai Institute of Immunology
09:20-09:35 Strategic Roadmap for Emerging Biopharma Companies Entering the Japanese Market
Motoki FUJII: Senior Official, Regulatory Affairs Division, EPS
09:35-09:50 R&D Landscape, Emerging Trends, and Opportunities in Autoimmune Diseases
Shuona Yuan: Senior Research Analyst, PharmCube
09:50-10:05 Practical Strategies and Case Studies in Global Clinical Development of Novel Oncology Drugs
Shengjun Zhang: General Manager, BioTrialMed
10:05-10:20 From Design to Detection: Precision Screening with End-to-End Guidance
Lei Huang: Head of Translational Medicine, Burning Rock Biotech
10:20-10:40 Break
10:40-10:55 Reshaping Translational R&D Decision-Making for Advanced Therapies and Novel Drug Modalities with QSP Models
Chen Zhao: Professor and Ph.D. Supervisor, Nanjing Medical University; Distinguished Medical Expert of Jiangsu Province
10:55-11:10 Innovative Therapies Session: Next-Generation Fully Humanized Mouse Models Empowering Breakthroughs in Oncology and Autoimmune R&D
Wenxin Liu: Head of Immuno-Oncology Pipeline, GenNovo Biotech
11:10-11:25 Innovative TIL Therapy: Redefining the Treatment Landscape for Solid Tumors
Zhenjiu Wang: CMO, HUASAIBIO
11:25-11:40 The Ways to Enhance Efficacy and Avoid Risks in Preclinical Research of Anti-Tumor and Self Immune New Drugs
Jian Ge: Executive Vice President, Preclinical Research Division, Medicilon